Staidson Beijing Biopharma Working Capital to Net Assets Ratio
Staidson Beijing Biopharma working capital to net assets ratio. Staidson Beijing Biopharma (300204) has a Working Capital to Net Assets ratio of 16.5% as of March 2026. Working capital of CN¥131.32 Million (current assets of CN¥262.42 Million minus current liabilities of CN¥131.10 Million) is measured against net assets of CN¥794.92 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Staidson Beijing Biopharma (2007–2025)
Working capital to net assets ratio of Staidson Beijing Biopharma from 2007 to 2025. This chart shows how Staidson Beijing Biopharma's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 16.5%, reflecting working capital of CN¥131.32 Million against net assets of CN¥794.92 Million CNY. Explore Staidson Beijing Biopharma (300204) investment intensity to see how much of total assets are deployed in long-term investments.
Staidson Beijing Biopharma Working Capital to Net Assets Ratio by Year (2007–2025)
Staidson Beijing Biopharma working capital to net assets ratio by year from 2007 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Staidson Beijing Biopharma from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Staidson Beijing Biopharma assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.6% | CN¥77.10 Million | CN¥806.72 Million | CN¥252.65 Million | CN¥175.55 Million | ▲ +7.0 pp |
| 2024 | 2.5% | CN¥23.18 Million | CN¥916.76 Million | CN¥177.62 Million | CN¥154.45 Million | ▼ -0.5 pp |
| 2023 | 3.0% | CN¥30.72 Million | CN¥1.02 Billion | CN¥238.89 Million | CN¥208.17 Million | ▼ -18.9 pp |
| 2022 | 22.0% | CN¥297.28 Million | CN¥1.35 Billion | CN¥529.06 Million | CN¥231.77 Million | ▼ -9.8 pp |
| 2021 | 31.7% | CN¥491.80 Million | CN¥1.55 Billion | CN¥688.44 Million | CN¥196.64 Million | ▼ -11.9 pp |
| 2020 | 43.6% | CN¥692.89 Million | CN¥1.59 Billion | CN¥903.32 Million | CN¥210.43 Million | ▼ -7.9 pp |
| 2019 | 51.5% | CN¥842.80 Million | CN¥1.64 Billion | CN¥1.02 Billion | CN¥178.37 Million | ▼ -2.2 pp |
| 2018 | 53.7% | CN¥1.32 Billion | CN¥2.46 Billion | CN¥1.55 Billion | CN¥232.66 Million | ▼ -12.9 pp |
| 2017 | 66.6% | CN¥1.47 Billion | CN¥2.21 Billion | CN¥1.82 Billion | CN¥348.13 Million | ▼ -8.6 pp |
| 2016 | 75.2% | CN¥1.44 Billion | CN¥1.92 Billion | CN¥1.84 Billion | CN¥399.08 Million | ▼ -5.9 pp |
| 2015 | 81.1% | CN¥1.37 Billion | CN¥1.68 Billion | CN¥1.72 Billion | CN¥353.37 Million | ▲ +0.7 pp |
| 2014 | 80.4% | CN¥1.22 Billion | CN¥1.51 Billion | CN¥1.47 Billion | CN¥257.68 Million | ▲ +3.5 pp |
| 2013 | 76.8% | CN¥1.01 Billion | CN¥1.31 Billion | CN¥1.23 Billion | CN¥218.95 Million | ▼ -0.4 pp |
| 2012 | 77.3% | CN¥958.65 Million | CN¥1.24 Billion | CN¥1.12 Billion | CN¥157.48 Million | ▼ -4.9 pp |
| 2011 | 82.2% | CN¥905.94 Million | CN¥1.10 Billion | CN¥932.56 Million | CN¥26.62 Million | ▲ +26.4 pp |
| 2010 | 55.8% | CN¥92.75 Million | CN¥166.23 Million | CN¥119.40 Million | CN¥26.66 Million | ▲ +8.7 pp |
| 2009 | 47.1% | CN¥56.39 Million | CN¥119.72 Million | CN¥80.92 Million | CN¥24.53 Million | ▲ +30.8 pp |
| 2008 | 16.3% | CN¥10.26 Million | CN¥62.82 Million | CN¥35.01 Million | CN¥24.75 Million | ▲ +45.8 pp |
| 2007 | -29.5% | CN¥-9.99 Million | CN¥33.87 Million | CN¥38.35 Million | CN¥48.35 Million | — |